PMID- 29955134
OWN - NLM
STAT- In-Data-Review
LR  - 20180801
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 119
IP  - 3
DP  - 2018 Aug
TI  - Characterisation of tumour microvessel density during progression of high-grade
      serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
PG  - 330-338
LID - 10.1038/s41416-018-0157-z [doi]
AB  - BACKGROUND: High-grade serous ovarian cancer (HGSOC) intratumoural vasculature
      evolution remains unknown. The study investigated changes in tumour microvessel
      density (MVD) in a large cohort of paired primary and recurrent HGSOC tissue
      samples and its impact on patients' clinico-pathological outcome. METHODS: A
      total of 222 primary (pOC) and recurrent (rOC) intra-patient paired HGSOC were
      assessed for immunohistochemical expression of angiogenesis-associated biomarkers
      (CD31, to evaluate MVD, and VEGF-A). Expression profiles were compared between
      pOCs and rOCs and correlated with patients' data. RESULTS: High intratumoural MVD
      and VEGF-A expression were observed in 75.7% (84/111) and 20.7% (23/111) pOCs,
      respectively. MVD(high) and VEGF((+)) samples were detected in 51.4% (57/111) and
      20.7% (23/111) rOCs, respectively. MVD(high)/VEGF((+)) co-expression was found in
      19.8% (22/111) and 8.1% (9/111) of pOCs and rOCs, respectively (p = 0.02).
      Pairwise analysis showed no significant change in MVD (p = 0.935) and VEGF-A (p =
      0.121) levels from pOCs to rOCs. MVD(high) pOCs were associated with higher
      CD3((+)) (p = 0.029) and CD8((+)) (p = 0.013) intratumoural effector TILs, while 
      VEGF((+)) samples were most frequently encountered among BRCA-mutated tumours (p 
      = 0.019). Multivariate analysis showed VEGF and MVD were not independent
      prognostic factors for OS. CONCLUSIONS: HGSOC intratumoural vasculature did not
      undergo significant changes during disease progression. High concentration of
      CD31((+)) vessels seems to promote recruitment of effector TILs. The study also
      provides preliminary evidence of the correlation between VEGF-positivity and BRCA
      status.
FAU - Ruscito, Ilary
AU  - Ruscito I
AD  - Department of Gynecology, European Competence Center for Ovarian Cancer, Campus
      Virchow Klinikum, Charite - Universitatsmedizin Berlin, Corporate member of Freie
      Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health,
      Berlin, Germany. ilary.ruscito@uniroma1.it.
AD  - Cell Therapy Unit and Laboratory of Tumor Immunology, Department of Experimental 
      Medicine, Sapienza University of Rome, Rome, Italy. ilary.ruscito@uniroma1.it.
FAU - Cacsire Castillo-Tong, Dan
AU  - Cacsire Castillo-Tong D
AD  - Translational Gynecology Group, Department of Obstetrics and Gynecology,
      Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel
      18-20, A-1090, Vienna, Austria.
FAU - Vergote, Ignace
AU  - Vergote I
AD  - Division of Gynaecological Oncology, Leuven Cancer Institute, Department of
      Gynaecology and Obstetrics, University Hospital Leuven, Catholic University of
      Leuven, Herestraat 49, B-3000, Leuven, Belgium.
FAU - Ignat, Iulia
AU  - Ignat I
AD  - Department of Gynecology, European Competence Center for Ovarian Cancer, Campus
      Virchow Klinikum, Charite - Universitatsmedizin Berlin, Corporate member of Freie
      Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health,
      Berlin, Germany.
FAU - Stanske, Mandy
AU  - Stanske M
AD  - Institute of Pathology, Charite - Universitatsmedizin Berlin, corporate member of
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of
      Health, Berlin, Germany.
FAU - Vanderstichele, Adriaan
AU  - Vanderstichele A
AD  - Division of Gynaecological Oncology, Leuven Cancer Institute, Department of
      Gynaecology and Obstetrics, University Hospital Leuven, Catholic University of
      Leuven, Herestraat 49, B-3000, Leuven, Belgium.
FAU - Glajzer, Jacek
AU  - Glajzer J
AD  - Department of Gynecology, European Competence Center for Ovarian Cancer, Campus
      Virchow Klinikum, Charite - Universitatsmedizin Berlin, Corporate member of Freie
      Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health,
      Berlin, Germany.
FAU - Kulbe, Hagen
AU  - Kulbe H
AD  - Department of Gynecology, European Competence Center for Ovarian Cancer, Campus
      Virchow Klinikum, Charite - Universitatsmedizin Berlin, Corporate member of Freie
      Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health,
      Berlin, Germany.
FAU - Trillsch, Fabian
AU  - Trillsch F
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich,
      Marchioninistrasse 15, Munich, Germany.
AD  - Department of Gynecology and Gynecologic Oncology, University Medical Center
      Hamburg-Eppendorf, Martinistr. 46, Hamburg, Germany.
FAU - Mustea, Alexander
AU  - Mustea A
AD  - Department of Gynecology and Obstetrics, University Medicine of Greifswald,
      Greifswald, Germany.
FAU - Kreuzinger, Caroline
AU  - Kreuzinger C
AD  - Translational Gynecology Group, Department of Obstetrics and Gynecology,
      Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel
      18-20, A-1090, Vienna, Austria.
FAU - Benedetti Panici, Pierluigi
AU  - Benedetti Panici P
AD  - Department of Gynecology, Obstetrics and Urology, Sapienza University of Rome,
      Rome, Italy.
FAU - Gourley, Charlie
AU  - Gourley C
AD  - Nicola Murray Centre for Ovarian Cancer Research, MRC IGMM, Western General
      Hospital, University of Edinburgh Cancer Research, UK Centre, Crewe Road South,
      Edinburgh, EH4 2XR, UK.
FAU - Gabra, Hani
AU  - Gabra H
AD  - Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial
      College London, London, UK.
AD  - Clinical Discovery Unit, AstraZeneca, Cambridge, UK.
FAU - Nuti, Marianna
AU  - Nuti M
AD  - Cell Therapy Unit and Laboratory of Tumor Immunology, Department of Experimental 
      Medicine, Sapienza University of Rome, Rome, Italy.
FAU - Taube, Eliane T
AU  - Taube ET
AD  - Institute of Pathology, Charite - Universitatsmedizin Berlin, corporate member of
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of
      Health, Berlin, Germany.
FAU - Kessler, Mirjana
AU  - Kessler M
AD  - Department of Molecular Biology, Max Planck Institute for Infection Biology,
      Berlin, Germany.
FAU - Sehouli, Jalid
AU  - Sehouli J
AD  - Department of Gynecology, European Competence Center for Ovarian Cancer, Campus
      Virchow Klinikum, Charite - Universitatsmedizin Berlin, Corporate member of Freie
      Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health,
      Berlin, Germany.
FAU - Darb-Esfahani, Silvia
AU  - Darb-Esfahani S
AD  - Institute of Pathology, Charite - Universitatsmedizin Berlin, corporate member of
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of
      Health, Berlin, Germany.
FAU - Braicu, Elena Ioana
AU  - Braicu EI
AD  - Department of Gynecology, European Competence Center for Ovarian Cancer, Campus
      Virchow Klinikum, Charite - Universitatsmedizin Berlin, Corporate member of Freie
      Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health,
      Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20180629
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
EDAT- 2018/06/30 06:00
MHDA- 2018/06/30 06:00
CRDT- 2018/06/30 06:00
PHST- 2018/02/18 00:00 [received]
PHST- 2018/06/01 00:00 [accepted]
PHST- 2018/05/22 00:00 [revised]
PHST- 2018/06/30 06:00 [pubmed]
PHST- 2018/06/30 06:00 [medline]
PHST- 2018/06/30 06:00 [entrez]
AID - 10.1038/s41416-018-0157-z [doi]
AID - 10.1038/s41416-018-0157-z [pii]
PST - ppublish
SO  - Br J Cancer. 2018 Aug;119(3):330-338. doi: 10.1038/s41416-018-0157-z. Epub 2018
      Jun 29.